PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’ antibody fragment after pulmonary delivery in three different species

International Journal of Pharmaceutics

Volumn 521, Issue 1-2, 2017, Pages 120-129

  Freches, Danielle ^a   Patil, Harshad P ^a   Machado Franco, Maria ^a   Uyttenhove, Catherine ^b   Heywood, Sam ^c   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c UCB PHARMA   (Belgium)

Author keywords

Monoclonal antibodies; PEGylation; Pulmonary drug delivery; Residence time; Rodents

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 17 ANTIBODY; MACROGOL; AUTOANTIBODY; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; LUNG; MALE; MOUSE; NONHUMAN; PEGYLATION; PRIORITY JOURNAL; RABBIT; RAT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NIH 3T3 CELL LINE; PROCEDURES; RABBITS AND HARES; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ANIMALS; AUTOANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; INTERLEUKIN-17; LUNG; MALE; MICE; NIH 3T3 CELLS; POLYETHYLENE GLYCOLS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 85013335849     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.02.021     Document Type: Article

References (33)

1. Brunner, G.A., Balent, B., Ellmerer, M., Schaupp, L., Siebenhofer, A., Jendle, J.H., Okikawa, J., Pieber, T.R., Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 44 (2001), 305–308.
2. Cantin, A.M., Woods, D.E., Cloutier, D., Dufour, E.K., Leduc, R., Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am. J. Respir. Cell Mol. Biol. 27 (2002), 659–665.
3. Chan, L.J., Ascher, D.B., Yadav, R., Bulitta, J.B., Williams, C.C., Porter, C.J., Landersdorfer, C.B., Kaminskas, L.M., Conjugation of 10 kDa linear PEG onto trastuzumab Fab’ is sufficient to significantly enhance lymphatic exposure while preserving in vitro biological activity. Mol. Pharm. 13 (2016), 1229–1241.
4. Chapman, A.P., Antoniw, P., Spitali, M., West, S., Stephens, S., King, D.J., Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17 (1999), 780–783.
5. Chapman, A.P., PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54 (2002), 531–545.
6. Desoubeaux, G., Reichert, J.M., Sleeman, M., Reckamp, K.L., Ryffel, B., Adamczewski, J.P., Sweeney, T.D., Vanbever, R., Diot, P., Owen, C.A., Page, C., Lerondel, S., Le Pape, A., Heuze-Vourc'h, N., Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives March 31–April 1, 2016, Tours, France. MAbs 8 (2016), 999–1009.
7. Detalle, L., Stohr, T., Palomo, C., Piedra, P.A., Gilbert, B.E., Mas, V., Millar, A., Power, U.F., Stortelers, C., Allosery, K., Melero, J.A., Depla, E., Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 60 (2016), 6–13.
8. Ducreux, J., Vanbever, R., Crocker, P.R., The inhibitory potencies of monoclonal antibodies to the macrophage adhesion molecule sialoadhesin are greatly increased following PEGylation. Bioconjug. Chem. 19 (2008), 2088–2094.
9. Fernandes, C.A., Vanbever, R., Preclinical models for pulmonary drug delivery. Expert Opin. Drug Deliv. 6 (2009), 1231–1245.
10. Garcia-Contreras, L., Morcol, T., Bell, S.J., Hickey, A.J., Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci, 5, 2003, E9.
11. Gopalakrishnan, M., Suarez, S., Hickey, A.J., Gobburu, J.V., Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J. Pharmacokinet. Pharmacodyn. 32 (2005), 485–500.
12. Guilleminault, L., Azzopardi, N., Arnoult, C., Sobilo, J., Herve, V., Montharu, J., Guillon, A., Andres, C., Herault, O., Le Pape, A., Diot, P., Lemarie, E., Paintaud, G., Gouilleux-Gruart, V., Heuze-Vourc'h, N., Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J. Control. Release 196 (2014), 344–354.
13. Hacha, J., Tomlinson, K., Maertens, L., Paulissen, G., Rocks, N., Foidart, J.M., Noel, A., Palframan, R., Gueders, M., Cataldo, D.D., Nebulized anti-IL-13 monoclonal antibody Fab’ fragment reduces allergen-induced asthma. Am. J. Respir. Cell Mol. Biol. 47 (2012), 709–717.
14. Harkema, J.R., Carey, S.A., Wagner, J.G., The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol. Pathol. 34 (2006), 252–269.
15. Heywood, S., 2007. Process for attaching effector molecules to proteins. Patent 2007003898 A1, 11/01/2007.
16. Hill, J., Eyles, J.E., Elvin, S.J., Healey, G.D., Lukaszewski, R.A., Titball, R.W., Administration of antibody to the lung protects mice against pneumonic plague. Infect. Immun. 74 (2006), 3068–3070.
17. Hofmann, W., Asgharian, B., The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol. Sci. 73 (2003), 448–456.
18. Jay, S.J., Johanson, W.G. Jr., Pierce, A.K., Reisch, J.S., Determinants of lung bacterial clearance in normal mice. J. Clin. Invest. 57 (1976), 811–817.
19. Koussoroplis, S.J., Heywood, S., Uyttenhove, C., Barilly, C., Van Snick, J., Vanbever, R., Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments. Int. J. Pharm. 454 (2013), 107–115.
20. Koussoroplis, S.J., Paulissen, G., Tyteca, D., Goldansaz, H., Todoroff, J., Barilly, C., Uyttenhove, C., Van Snick, J., Cataldo, D., Vanbever, R., PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control. Release 187 (2014), 91–100.
21. Kurfurst, M.M., Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200 (1992), 244–248.
22. Lightwood, D., O'Dowd, V., Carrington, B., Veverka, V., Carr, M.D., Tservistas, M., Henry, A.J., Smith, B., Tyson, K., Lamour, S., Bracher, M., Sarkar, K., Turner, A., Lawson, A.D., Bourne, T., Gozzard, N., Palframan, R., The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J. Mol. Biol. 425 (2013), 577–593.
23. Minne, A., Louahed, J., Mehauden, S., Baras, B., Renauld, J.C., Vanbever, R., The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122 (2007), 316–325.
24. Pasut, G., Veronese, F.M., State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161 (2012), 461–472.
25. Plopper, C.G., Halsebo, J.E., Berger, W.J., Sonstegard, K.S., Nettesheim, P., Distribution of nonciliated bronchiolar epithelial (Clara) cells in intra- and extrapulmonary airways of the rabbit. Exp. Lung Res. 5 (1983), 79–98.
26. Rave, K., Bott, S., Heinemann, L., Sha, S., Becker, R.H., Willavize, S.A., Heise, T., Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diab. Care 28 (2005), 1077–1082.
27. Reichert, J.M., Antibodies to watch in 2016. MAbs 8 (2016), 197–204.
28. Respaud, R., Marchand, D., Pelat, T., Tchou-Wong, K.M., Roy, C.J., Parent, C., Cabrera, M., Guillemain, J., Mac Loughlin, R., Levacher, E., Fontayne, A., Douziech-Eyrolles, L., Junqua-Moullet, A., Guilleminault, L., Thullier, P., Guillot-Combe, E., Vecellio, L., Heuze-Vourc'h, N., Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin. J. Control. Release 234 (2016), 21–32.
29. Schlesinger, R.B., Driscoll, K.E., Mucociliary clearance from the lungs of rabbits following single and intermittent exposures to ozone. J. Toxicol. Environ. Health 20 (1987), 125–134.
30. Stone, K.C., Mercer, R.R., Gehr, P., Stockstill, B., Crapo, J.D., Allometric relationships of cell numbers and size in the mammalian lung. Am. J. Respir. Cell Mol. Biol. 6 (1992), 235–243.
31. Todoroff, J., Vanbever, R., Fate of nanomedicines in the lungs. Curr. Opin. Colloid Interface Sci. 16 (2011), 246–254.
32. Van Heeke, G., Allosery, K., De Brabandere, V., De Smedt, T., Detalle, L., de Fougerolles, A., Nanobodies(R) as inhaled biotherapeutics for lung diseases. Pharmacol. Ther. 169 (2017), 47–56.
33. Veronese, F.M., Pasut, G., PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005), 1451–1458.